🇺🇸 FDA
Patent

US 12331334

Modified urokinase-type plasminogen activator polypeptides and methods of use

granted A61KA61K31/727A61K38/00

Quick answer

US patent 12331334 (Modified urokinase-type plasminogen activator polypeptides and methods of use) held by Vertex Pharmaceuticals Incorporated expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
65
CPC classes
A61K, A61K31/727, A61K38/00, A61K38/49, A61K45/06